Google’s deep-learning program for determining the 3D shapes of proteins stands to transform biology, say scientists.
Longevity biotech firm BioAge Labs is readying itself for clinical trials after raising a whopping $90 million Series C funding round. The company revealed it will be moving its lead platform-derived therapies, BGE-117 and BGE-175, into Phase 2 clinical trials in the first half of 2021.
Longevity. Technology: As the developer of an AI platform that maps the molecular pathways impacting human Longevity, we’ve followed developments at BioAge with great interest. With two compounds ready to enter the clinic next year, and more on the way, this company is fast-becoming one of Longevity’s most exciting prospects.
The new funds will be used to develop BioAge’s portfolio of therapies for increasing healthspan and lifespan, as well as to augment its AI platform, and further expand its capabilities to test drug candidates in predictive models of human diseases of aging.
But maybe an artificial earths core could allow for permanent inhabitantation.
Earth’s core is the very hot, very dense center of our planet.
The CDC issued a level four warning last month, it’s most severe, advising against all travel to Mexico.
However, those who choose to travel to Mexico should get a COVID-19 test between three and five days after they return. They should also quarantine at home for seven days.
Sounds important.
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
After controlling for various factors — such as participants’ age, sex, smoking status and activity level — the researchers found that taking glucosamine/chondroitin every day for a year or longer was associated with a 39 percent reduction in all-cause mortality.
It was also linked to a 65 percent reduction in cardiovascular-related deaths. That’s a category that includes deaths from stroke, coronary artery disease and heart disease, the United States’ biggest killer.” “He explains that because this is an epidemiological study — rather than a clinical trial — it doesn’t offer definitive proof that glucosamine/chondroitin makes death less likely. But he does call the results “encouraging.””.
Glucosamine supplements may reduce overall mortality about as well as regular exercise does, according to a new epidemiological study from West Virginia University.
“Does this mean that if you get off work at five o’clock one day, you should just skip the gym, take a glucosamine pill and go home instead?” said Dana King, professor and chair of the Department of Family Medicine, who led the study. “That’s not what we suggest. Keep exercising, but the thought that taking a pill would also be beneficial is intriguing.”
He and his research partner, Jun Xiang — a WVU health data analyst — assessed data from 16,686 adults who completed the National Health and Nutrition Examination Survey from 1999 to 2010. All of the participants were at least 40 years old. King and Xiang merged these data with 2015 mortality figures.
“The Boy Who Died Wolf” AVAILABLE EVERYWHERE
►DOWNLOAD: http://flyt.it/HighlySuspectTheBoyWhoDiedWolf.
►Spotify: http://flyt.it/TheBoyWhoDiedWolfSpotify.
►Apple Music: http://flyt.it/TheBoyWhoDiedWolfAp.
►Amazon: http://flyt.it/HighlySuspectTheBoyWhoDiedWolfAm.
►Google Play: http://flyt.it/HighlySuspectTheBoyWhoDiedWolfGp.
https://www.highlysuspect.net/confessional.
-
IBM security researchers said the “precision targeting of executives and key global organizations hold the potential hallmarks of a nation-state tradecraft.”
One Dutch-Irish company is leading the way towards greener roads, by selling cheap electric conversion kits for existing petrol or diesel cars.
Drivers will be able to cut their carbon footprints by trading in an old car running on fossil fuel and turning it into a functioning, battery-operated electric vehicle.
Based just south of Dublin, New Electric claims to be able to “future proof” cars for years to come, no matter the brand, the desired speed, or torque. Its mission is to take good quality cars that may have been sent to the scrap heap and revamp them by installing batteries.